A Drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5388-5395

  Kamal, Mohamed A ^a   Gieschke, Ronald ^b   Lemenuel Diot, Annabelle ^b   Beauchemin, Catherine A A ^c   Smith, Patrick F ^d,e   Rayner, Craig R ^d,f  

^a Roche Pharmaceutical Research and Early Development   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c RYERSON UNIVERSITY   (Canada)

^d D3 Medicine LLC   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PLACEBO; ANTIVIRUS AGENT; SIALIDASE;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG CLEARANCE; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA VIRUS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TARGET CELL; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS INFECTIVITY; VIRUS RELEASE; VIRUS SHEDDING; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; ORTHOMYXOVIRIDAE;

ANTIVIRAL AGENTS; MODELS, BIOLOGICAL; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR;

EID: 84940910772     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00069-15     Document Type: Article

References (26)

1. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845- 1850. http://dx.doi.org/10.1016/S0140-6736(00)02288-1.
2. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016-1024. http://dx.doi.org/10.1001/jama.283.8.1016.
3. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soerso S, Uyeki TM. 2008. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358:261-273. http://dx.doi.org/10 .1056/NEJMra0707279.
4. Butler D. 2005. Wartime tactic doubles power of scare bird-flu drug. Nature 438:6. http://dx.doi.org/10.1038/438006a.
5. Howton JC. 2006. Probenecid with oseltamivir for human influenza A (H5N1) virus infection? N Engl J Med 354:879-880. http://dx.doi.org/10 .1056/NEJMc052422.
6. Baccam P, Beauchemin CA, Macken CA, Hayden FG, Perelson AS. 2006. Kinetics of influenza A virus infection in humans. J Virol 80:7590-7599. http://dx.doi.org/10.1128/JVI.01623-05.
7. Beauchemin CA, Handel A. 2011. A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health 11(Suppl 1):S7. http://dx.doi.org /10.1186/1471-2458-11-S1-S7.
8. Perelson AS. 2002. Modelling viral and immune system dynamics. Nat Rev Immunol 2:28-36. http://dx.doi.org/10.1038/nri700.
9. Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N. 2010. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87:706-713. http://dx.doi.org/10.1038/clpt.2010.35.
10. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240-1246. http: //dx.doi.org/10.1001/jama.282.13.1240.
11. Gibiansky L, Gibiansky E, Bauer R. 2012. Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a targetmediated drug disposition model. J Pharmacokinet Pharmacodyn 39:17-35. http://dx.doi.org/10.1007/s10928-011-9228-y.
12. Sheiner LB, Beal SL. 1980. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8:553-571.
13. Ménache MG, Hanna LM, Gross EA, Lou SR, Zinreich SJ, Leopold DA, Jarabek AM, Miller FJ. 1997. Upper respiratory tract surface areas and volumes of laboratory animals and humans: considerations for dosimetry models. J Toxicol Environ Health 50:475-506. http://dx.doi.org/10.1080 /009841097160366.
14. Fedoseev GB, Geharev SS. 1989. Basic defence mechanisms of bronchiolung system, p 112-144. In Outov NV (ed), General pulmonology, vol 1. Medicina, Moscow, Russia.
15. Karlsson MO, Holford N. 2008. A tutorial on visual predictive checks, abstr 1434. Abstr 17th Annu Meet Population Approach Group, Marseille, France.
16. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 77:8418-8425. http://dx.doi.org/10.1128/JVI.77.15.8418-8425.2003.
17. Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A. 2013. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother 57:3478-3487. http://dx.doi.org/10.1128/AAC.02440-12.
18. Canini L, Conway JM, Perelson AS, Carrat F. 2014. Impact of different oseltamivir regimens on treating influenzaAvirus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol 10: e1003568. http://dx.doi.org/10.1371/journal.pcbi.1003568.
19. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P, IMPACT Study Group. 2003. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51:123-129. http://dx.doi.org/10.1093 /jac/dkg007.
20. Heinonen S, Silvennoinen H, Lehtinen P, Vainionp R, Vahlberg T, Ziegler T, Ikonen N, Puhakka T, Heikkinen T. 2010. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 51:887-894. http://dx.doi.org/10.1086 /656408.
21. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, Lui GC, Wong BC, Wong RY, Lam WY, Chu IM, Lai RW, Cockram CS, Sung JJ. 2009. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 200:492-500. http://dx.doi.org/10 .1086/600383.
22. Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, Hagey R, Voell J, Fiorentino C, Ademposi A, Shoham S, Taubenberger JK. 2014. The natural history of influenza infection in the severely immunocompromised versus non-immunocompromised hosts. Clin Infect Dis 58:214-224. http://dx.doi.org/10.1093/cid/cit725.
23. Du L, Jin L, Zhao G, Sun S, Li J, Yu H, Li Y, Zheng BJ, Liddington RC, Zhou Y, Jiang S. 2013. Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol 87:2215-2225. http://dx.doi .org/10.1128/JVI.02344-12.
24. Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. 2011. Neuraminidase inhibitors for treatment of human and avian strain influenza: a comparative modeling study. J Theor Biol 269:234-244. http: //dx.doi.org/10.1016/j.jtbi.2010.10.017.
25. Canini L, Carrat F. 2011. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85:2764-2770. http://dx .doi.org/10.1128/JVI.01318-10.
26. Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CAA. 2013. Assessing mathematical models of influenza infections using features of the immune response. PLoS One 28:e57088.